StockNews.com Begins Coverage on Agile Therapeutics (NASDAQ:AGRX)

StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report released on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Stock Performance

NASDAQ AGRX opened at $1.46 on Friday. The firm has a market capitalization of $10.01 million, a PE ratio of -0.40 and a beta of 1.58. The business’s 50-day moving average price is $1.22 and its two-hundred day moving average price is $0.80. Agile Therapeutics has a 12 month low of $0.20 and a 12 month high of $2.63.

Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter. The company had revenue of $5.58 million during the quarter.

Institutional Trading of Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC increased its stake in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 108,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,000 shares during the quarter. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent reporting period. 10.92% of the stock is owned by hedge funds and other institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.